Acute coronary syndrome risk stratification: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 13: Line 13:
|-
|-
| bgcolor="LightGreen"|
| bgcolor="LightGreen"|
<nowiki>"</nowiki>'''1.''' A rapid clinical determination of the likelihood risk of obstructive [[CAD]] (i.e., high, intermediate, or low) should be made in all patients with [[chest discomfort]] or other symptoms suggestive of an [[ACS]] and considered in patient management. ''(Level of Evidence: C)''<nowiki>"</nowiki>
<nowiki>"</nowiki>'''1.''' A rapid clinical determination of the likelihood risk of obstructive [[CAD]] (i.e., high, intermediate, or low) should be made in all patients with [[chest discomfort]] or other symptoms suggestive of an [[ACS]] and considered in patient management. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level C]])''<nowiki>"</nowiki>
|-
|-
| bgcolor="LightGreen"|
| bgcolor="LightGreen"|
<nowiki>"</nowiki>'''2.''' Patients who present with [[chest discomfort]] or other [[ischemic symptoms]] should undergo early risk stratification for the risk of cardiovascular events (e.g., death or [re][[MI]]) that focuses on history, including anginal symptoms, physical findings, [[ECG]] findings, and [[biomarkers]] of cardiac injury and results should be considered in patient management. ''(Level of Evidence: C)''<nowiki>"</nowiki>
<nowiki>"</nowiki>'''2.''' Patients who present with [[chest discomfort]] or other [[ischemic symptoms]] should undergo early risk stratification for the risk of cardiovascular events (e.g., death or [re][[MI]]) that focuses on history, including anginal symptoms, physical findings, [[ECG]] findings, and [[biomarkers]] of cardiac injury and results should be considered in patient management. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level C]])''<nowiki>"</nowiki>
|-
|-
| bgcolor="LightGreen"|
| bgcolor="LightGreen"|
<nowiki>"</nowiki>'''3.''' A [[12-lead ECG]] should be performed and shown to an experienced [[emergency physician]] as soon as possible after [[ED]] arrival, with a goal of within 10 min of [[ED]] arrival for all patients with [[chest discomfort]] (or anginal equivalent) or other symptoms suggestive of [[ACS]]. ''(Level of Evidence: B)''<nowiki>"</nowiki>
<nowiki>"</nowiki>'''3.''' A [[12-lead ECG]] should be performed and shown to an experienced [[emergency physician]] as soon as possible after [[ED]] arrival, with a goal of within 10 min of [[ED]] arrival for all patients with [[chest discomfort]] (or anginal equivalent) or other symptoms suggestive of [[ACS]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level B]])''<nowiki>"</nowiki>
|-
|-
| bgcolor="LightGreen"|
| bgcolor="LightGreen"|
<nowiki>"</nowiki>'''4.''' If the initial [[ECG]] is not diagnostic but the patient remains symptomatic and there is high clinical suspicion for [[ACS]], serial [[ECG]]s, initially at 15- to 30-min intervals, should be performed to detect the potential for development of ST-segment elevation or depression. ''(Level of Evidence: B)''<nowiki>"</nowiki>
<nowiki>"</nowiki>'''4.''' If the initial [[ECG]] is not diagnostic but the patient remains symptomatic and there is high clinical suspicion for [[ACS]], serial [[ECG]]s, initially at 15- to 30-min intervals, should be performed to detect the potential for development of ST-segment elevation or depression. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level B]])''<nowiki>"</nowiki>
|-
|-
| bgcolor="LightGreen"|
| bgcolor="LightGreen"|
<nowiki>"</nowiki>'''5.''' [[Cardiac biomarkers]] should be measured in all patients who present with [[chest discomfort]] consistent with [[ACS]]. ''(Level of Evidence: B)''<nowiki>"</nowiki>
<nowiki>"</nowiki>'''5.''' [[Cardiac biomarkers]] should be measured in all patients who present with [[chest discomfort]] consistent with [[ACS]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level B]])''<nowiki>"</nowiki>
|-
|-
| bgcolor="LightGreen"|
| bgcolor="LightGreen"|
<nowiki>"</nowiki>'''6.''' A cardiac-specific [[troponin]] is the preferred marker, and if available, it should be measured in all patients who present with [[chest discomfort]] consistent with [[ACS]]. ''(Level of Evidence: B)''<nowiki>"</nowiki>
<nowiki>"</nowiki>'''6.''' A cardiac-specific [[troponin]] is the preferred marker, and if available, it should be measured in all patients who present with [[chest discomfort]] consistent with [[ACS]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level B]])''<nowiki>"</nowiki>
|-
|-
| bgcolor="LightGreen"|
| bgcolor="LightGreen"|
<nowiki>"</nowiki>'''7.''' Patients with negative [[cardiac biomarkers]] within 6 h of the onset of symptoms consistent with [[ACS]] should have [[biomarkers]] remeasured in the time frame of 8 to 12 h after symptom onset. (The exact timing of serum marker measurement should take into account the uncertainties often present with the exact timing of onset of pain and the sensitivity, precision, and institutional norms of the assay being utilized as well as the release kinetics of the marker being measured.) ''(Level of Evidence: B)''<nowiki>"</nowiki>
<nowiki>"</nowiki>'''7.''' Patients with negative [[cardiac biomarkers]] within 6 h of the onset of symptoms consistent with [[ACS]] should have [[biomarkers]] remeasured in the time frame of 8 to 12 h after symptom onset. (The exact timing of serum marker measurement should take into account the uncertainties often present with the exact timing of onset of pain and the sensitivity, precision, and institutional norms of the assay being utilized as well as the release kinetics of the marker being measured.) ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level B]])''<nowiki>"</nowiki>
|-
|-
| bgcolor="LightGreen"|
| bgcolor="LightGreen"|
<nowiki>"</nowiki>'''8.''' The initial evaluation of the patient with suspected [[ACS]] should include the consideration of noncoronary causes for the development of unexplained symptoms. ''(Level of Evidence: C)''<nowiki>"</nowiki>
<nowiki>"</nowiki>'''8.''' The initial evaluation of the patient with suspected [[ACS]] should include the consideration of noncoronary causes for the development of unexplained symptoms. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level C]])''<nowiki>"</nowiki>
|}
|}


Line 42: Line 42:
|-
|-
|bgcolor="LightCoral"|
|bgcolor="LightCoral"|
<nowiki>"</nowiki>'''1.''' Total [[CK]] (without [[MB]]), [[aspartate aminotransferase]] ([[AST]], [[SGOT]]), [[alanine transaminase]], [[beta-hydroxybutyric dehydrogenase]], and/or [[lactate dehydrogenase]] should not be utilized as primary tests for the detection of myocardial injury in patients with [[chest discomfort]] suggestive of [[ACS]]. ''(Level of Evidence: C)''<nowiki>"</nowiki>
<nowiki>"</nowiki>'''1.''' Total [[CK]] (without [[MB]]), [[aspartate aminotransferase]] ([[AST]], [[SGOT]]), [[alanine transaminase]], [[beta-hydroxybutyric dehydrogenase]], and/or [[lactate dehydrogenase]] should not be utilized as primary tests for the detection of myocardial injury in patients with [[chest discomfort]] suggestive of [[ACS]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level C]])''<nowiki>"</nowiki>
|}
|}


Line 50: Line 50:
|-
|-
|bgcolor="LemonChiffon"|
|bgcolor="LemonChiffon"|
<nowiki>"</nowiki>'''1.''' Use of risk-stratification models, such as the Thrombolysis In Myocardial Infarction (TIMI) or Global Registry of Acute Coronary Events (GRACE) risk score or the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) risk model, can be useful to assist in decision making with regard to treatment options in patients with suspected [[ACS]]. ''(Level of Evidence: B)''<nowiki>"</nowiki>
<nowiki>"</nowiki>'''1.''' Use of risk-stratification models, such as the Thrombolysis In Myocardial Infarction (TIMI) or Global Registry of Acute Coronary Events (GRACE) risk score or the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) risk model, can be useful to assist in decision making with regard to treatment options in patients with suspected [[ACS]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level B]])''<nowiki>"</nowiki>
|-
|-
|bgcolor="LemonChiffon"|
|bgcolor="LemonChiffon"|
<nowiki>"</nowiki>'''2.''' It is reasonable to remeasure positive [[biomarkers]] at 6- to 8-h intervals 2 to 3 times or until levels have peaked, as an index of infarct size and dynamics of [[necrosis]]. ''(Level of Evidence: B)''<nowiki>"</nowiki>
<nowiki>"</nowiki>'''2.''' It is reasonable to remeasure positive [[biomarkers]] at 6- to 8-h intervals 2 to 3 times or until levels have peaked, as an index of infarct size and dynamics of [[necrosis]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level B]])''<nowiki>"</nowiki>
|-
|-
|bgcolor="LemonChiffon"|
|bgcolor="LemonChiffon"|
<nowiki>"</nowiki>'''3.''' It is reasonable to obtain supplemental [[ECG]] leads V7 through V9 in patients whose initial [[ECG]] is nondiagnostic to rule out [[MI]] due to [[left circumflex]] occlusion. ''(Level of Evidence: B)''<nowiki>"</nowiki>
<nowiki>"</nowiki>'''3.''' It is reasonable to obtain supplemental [[ECG]] leads V7 through V9 in patients whose initial [[ECG]] is nondiagnostic to rule out [[MI]] due to [[left circumflex]] occlusion. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level B]])''<nowiki>"</nowiki>
|-
|-
|bgcolor="LemonChiffon"|
|bgcolor="LemonChiffon"|
<nowiki>"</nowiki>'''4.''' Continuous [[12-lead ECG]] monitoring is a reasonable alternative to serial 12-lead recordings in patients whose initial [[ECG]] is nondiagnostic. ''(Level of Evidence: B)''<nowiki>"</nowiki>
<nowiki>"</nowiki>'''4.''' Continuous [[12-lead ECG]] monitoring is a reasonable alternative to serial 12-lead recordings in patients whose initial [[ECG]] is nondiagnostic. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level B]])''<nowiki>"</nowiki>
|}
|}


Line 67: Line 67:
|-
|-
|bgcolor="LemonChiffon"|
|bgcolor="LemonChiffon"|
<nowiki>"</nowiki>'''1.''' For patients who present within 6 h of the onset of symptoms consistent with [[ACS]], assessment of an early marker of cardiac injury (e.g., [[myoglobin]]) in conjunction with a late marker (e.g., [[troponin]]) may be considered. ''(Level of Evidence: B)''<nowiki>"</nowiki>
<nowiki>"</nowiki>'''1.''' For patients who present within 6 h of the onset of symptoms consistent with [[ACS]], assessment of an early marker of cardiac injury (e.g., [[myoglobin]]) in conjunction with a late marker (e.g., [[troponin]]) may be considered. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level B]])''<nowiki>"</nowiki>
|-
|-
|bgcolor="LemonChiffon"|
|bgcolor="LemonChiffon"|
<nowiki>"</nowiki>'''2.''' For patients who present within 6 h of symptoms suggestive of [[ACS]], a 2-h delta [[CK-MB mass]] in conjunction with 2-h delta [[troponin]] may be considered. ''(Level of Evidence: B)''<nowiki>"</nowiki>
<nowiki>"</nowiki>'''2.''' For patients who present within 6 h of symptoms suggestive of [[ACS]], a 2-h delta [[CK-MB mass]] in conjunction with 2-h delta [[troponin]] may be considered. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level B]])''<nowiki>"</nowiki>
|-
|-
|bgcolor="LemonChiffon"|
|bgcolor="LemonChiffon"|
<nowiki>"</nowiki>'''3.''' For patients who present within 6 h of symptoms suggestive of [[ACS]], [[myoglobin]] in conjunction with [[CK-MB mass]] or [[troponin]] when measured at baseline and 90 min may be considered. ''(Level of Evidence: B)''<nowiki>"</nowiki>
<nowiki>"</nowiki>'''3.''' For patients who present within 6 h of symptoms suggestive of [[ACS]], [[myoglobin]] in conjunction with [[CK-MB mass]] or [[troponin]] when measured at baseline and 90 min may be considered. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level B]])''<nowiki>"</nowiki>
|-
|-
|bgcolor="LemonChiffon"|
|bgcolor="LemonChiffon"|
<nowiki>"</nowiki>'''4.''' Measurement of [[BNP]] or [[NT-pro-BNP]] may be considered to supplement assessment of global risk in patients with suspected [[ACS]]. ''(Level of Evidence: B)''<nowiki>"</nowiki>
<nowiki>"</nowiki>'''4.''' Measurement of [[BNP]] or [[NT-pro-BNP]] may be considered to supplement assessment of global risk in patients with suspected [[ACS]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level B]])''<nowiki>"</nowiki>
|}
|}


Revision as of 13:06, 10 October 2012

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Risk Stratification

ACC / AHA 2007 Guidelines for Acute Coronary Syndrome Early Risk Stratification (DO NOT EDIT)[1]

Class I

"1. A rapid clinical determination of the likelihood risk of obstructive CAD (i.e., high, intermediate, or low) should be made in all patients with chest discomfort or other symptoms suggestive of an ACS and considered in patient management. (Level C)"

"2. Patients who present with chest discomfort or other ischemic symptoms should undergo early risk stratification for the risk of cardiovascular events (e.g., death or [re]MI) that focuses on history, including anginal symptoms, physical findings, ECG findings, and biomarkers of cardiac injury and results should be considered in patient management. (Level C)"

"3. A 12-lead ECG should be performed and shown to an experienced emergency physician as soon as possible after ED arrival, with a goal of within 10 min of ED arrival for all patients with chest discomfort (or anginal equivalent) or other symptoms suggestive of ACS. (Level B)"

"4. If the initial ECG is not diagnostic but the patient remains symptomatic and there is high clinical suspicion for ACS, serial ECGs, initially at 15- to 30-min intervals, should be performed to detect the potential for development of ST-segment elevation or depression. (Level B)"

"5. Cardiac biomarkers should be measured in all patients who present with chest discomfort consistent with ACS. (Level B)"

"6. A cardiac-specific troponin is the preferred marker, and if available, it should be measured in all patients who present with chest discomfort consistent with ACS. (Level B)"

"7. Patients with negative cardiac biomarkers within 6 h of the onset of symptoms consistent with ACS should have biomarkers remeasured in the time frame of 8 to 12 h after symptom onset. (The exact timing of serum marker measurement should take into account the uncertainties often present with the exact timing of onset of pain and the sensitivity, precision, and institutional norms of the assay being utilized as well as the release kinetics of the marker being measured.) (Level B)"

"8. The initial evaluation of the patient with suspected ACS should include the consideration of noncoronary causes for the development of unexplained symptoms. (Level C)"

Class III

"1. Total CK (without MB), aspartate aminotransferase (AST, SGOT), alanine transaminase, beta-hydroxybutyric dehydrogenase, and/or lactate dehydrogenase should not be utilized as primary tests for the detection of myocardial injury in patients with chest discomfort suggestive of ACS. (Level C)"

Class IIa

"1. Use of risk-stratification models, such as the Thrombolysis In Myocardial Infarction (TIMI) or Global Registry of Acute Coronary Events (GRACE) risk score or the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) risk model, can be useful to assist in decision making with regard to treatment options in patients with suspected ACS. (Level B)"

"2. It is reasonable to remeasure positive biomarkers at 6- to 8-h intervals 2 to 3 times or until levels have peaked, as an index of infarct size and dynamics of necrosis. (Level B)"

"3. It is reasonable to obtain supplemental ECG leads V7 through V9 in patients whose initial ECG is nondiagnostic to rule out MI due to left circumflex occlusion. (Level B)"

"4. Continuous 12-lead ECG monitoring is a reasonable alternative to serial 12-lead recordings in patients whose initial ECG is nondiagnostic. (Level B)"

Class IIb

"1. For patients who present within 6 h of the onset of symptoms consistent with ACS, assessment of an early marker of cardiac injury (e.g., myoglobin) in conjunction with a late marker (e.g., troponin) may be considered. (Level B)"

"2. For patients who present within 6 h of symptoms suggestive of ACS, a 2-h delta CK-MB mass in conjunction with 2-h delta troponin may be considered. (Level B)"

"3. For patients who present within 6 h of symptoms suggestive of ACS, myoglobin in conjunction with CK-MB mass or troponin when measured at baseline and 90 min may be considered. (Level B)"

"4. Measurement of BNP or NT-pro-BNP may be considered to supplement assessment of global risk in patients with suspected ACS. (Level B)"

See Also

Sources

  • The ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction [1]

References

  1. ↑ 1.0 1.1 Anderson JL, Adams CD, Antman EM; et al. (2007). "ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine". JACC. 50 (7): e1–e157. PMID 17692738. Text "doi:10.1016/j.jacc.2007.02.013 " ignored (help); Unknown parameter |month= ignored (help)

ur:تاجی متلازمۂ حاد


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Acute_coronary_syndrome_risk_stratification&oldid=770752"